Keyphrases
Relapsed Disease
100%
Aggressive B-cell non-Hodgkin Lymphoma
100%
Therapeutic Development
50%
Tumor Cells
50%
Immune System
50%
Mode of Delivery
50%
Manufacturing Process
50%
T Cells
50%
Lymphoma
50%
Older Patients
50%
Manufacturing Cost
50%
Poor Outcome
50%
Immuno-oncology
50%
Dosing Schedule
50%
Treatment Paradigms
50%
Rapid Development
50%
Rituximab
50%
Nervous System Diseases
50%
Relapse Risk
50%
Therapeutic Combinations
50%
High-grade B-cell Lymphoma
50%
Rational Combinations
50%
CD20
50%
B-cell non-Hodgkin Lymphoma (B-NHL)
50%
Anti-CD20 Antibody
50%
Primary Refractory Disease
50%
Third-line Therapy
50%
Cell Construct
50%
Bispecific Antibody
50%
Antitumor Potential
50%
Cancer Histology
50%
CD3 Bispecific
50%
CD19 chimeric Antigen Receptor T Cells
50%
Medicine and Dentistry
Diseases
100%
Non-Hodgkin Lymphoma
100%
B Cell
100%
Immunotherapy
100%
CD20
66%
Tumor Cell
33%
Rituximab
33%
Immune System
33%
Immunoglobulin
33%
Malignant Neoplasm
33%
B-Cell Lymphoma
33%
Health Care Cost
33%
Central Nervous System Disease
33%
CD3 Antigen
33%
Bispecific Antibody
33%
Chimeric Antigen Receptor T-Cell
33%
T Cell
33%
Oncology
33%
Monoclonal Antibody
33%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Disease
100%
Immunotherapy
100%
Malignant Neoplasm
33%
Immunoglobulin
33%
B Cell Lymphoma
33%
Central Nervous System Disease
33%
Rituximab
33%
Chimeric Antigen Receptor
33%
Bispecific Antibody
33%
Neoplasm
33%
Monoclonal Antibody
33%
CD3 Antigen
33%
Neuroscience
B Cell
100%
Immunotherapy
100%
Non-Hodgkin Lymphoma
75%
CD20
50%
T Cell
50%
Intravenous Immunoglobulin
25%
Monoclonal Antibody
25%
CD19
25%
Central Nervous System Disease
25%
Rituximab
25%
Chimeric Antigen Receptor
25%
CD3 Antigen
25%
Bispecific Antibody
25%